A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and implementation of multi-national observational studies for post-marketing drug safety assessment, addressing growing needs for global evidence in regulatory decision-making.
This article was originally published on MedicalXpress.com

